Innate Pharma SA

20-F13D13G

Schedule 13D - Activist Investments

NASDAQ
IPHA
Innate Pharma SA
SCHEDULE: AstraZeneca Maintains 8.3% Stake in Innate Pharma
AstraZeneca PLC, through its subsidiary MedImmune Limited, has reaffirmed its 8.3% beneficial ownership in Innate Pharma SA.
NASDAQ
IPHA
Innate Pharma SA
SCHEDULE 13D/A: French State-Backed Entities Adjust Innate Pharma SA Ownership Disclosure Following Share Dilution
Several French state-backed entities, including Bpifrance Participations and Caisse des Dépôts, have updated their Schedule 13D filing for Innate Pharma SA, reflecting a decreased percentage ownership due to an increase in the Issuer's outstanding shares, not through their own transactions.
Capital raise

Schedule 13G - Passive Investments

NASDAQ
IPHA
Innate Pharma SA
SCHEDULE: Novo Nordisk Discloses 5.03% Stake in Innate Pharma
Novo Nordisk A/S has reported a beneficial ownership of 5.03% in Innate Pharma SA's ordinary shares as of March 31, 2026.
NASDAQ
IPHA
Innate Pharma SA
SCHEDULE: Novo Nordisk Discloses 7.82% Stake in Innate Pharma
Novo Nordisk A/S has reported a 7.82% beneficial ownership stake in Innate Pharma SA, holding 7,333,778 ordinary shares.
NASDAQ
IPHA
Innate Pharma SA
SCHEDULE: Novo Nordisk Discloses 9.65% Stake in Innate Pharma
Novo Nordisk A/S has disclosed a 9.65% beneficial ownership stake in Innate Pharma SA, as reported in an amended Schedule 13G filing.
NASDAQ
IPHA
Innate Pharma SA
SCHEDULE 13G/A: Sanofi Discloses 9.05% Stake in Innate Pharma SA via Amended SEC Filing
Sanofi has filed an amended Schedule 13G, revealing its beneficial ownership of 9.05% of Innate Pharma SA's ordinary shares as of April 23, 2025.
NASDAQ
IPHA
Innate Pharma SA
SCHEDULE 13G: Sanofi Discloses 9.05% Stake in Innate Pharma SA
Sanofi has filed a Schedule 13G, revealing a beneficial ownership of 9.05% of Innate Pharma SA's ordinary shares.